SCHEMBL7887698

SCHEMBL7887698

N[C@H](C(=O)O)c1ccccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47
GABRA1 P14867 1/20 0.46
GABRB2 P47870 1/20 0.46
GRM1 Q13255 7/20 0.44
KDM4E B2RXH2 6/20 0.43
ALDH1A1 P00352 6/20 0.43
HPGD P15428 6/20 0.43
HSD17B10 Q99714 5/20 0.43
TDP1 Q9NUW8 4/20 0.43
GRM2 Q14416 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 1/20 0.43
TSHR P16473 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HMGB1 P09429 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3441250 1.00 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4GABRA1
SCHEMBL9420931 1.00 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4GABRA1
SCHEMBL29672969 1.00 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4GABRA1
SCHEMBL29672962 1.00 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4GABRA1
SCHEMBL7886248 1.00 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4GABRA1
SCHEMBL29419355 1.00 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4GABRA1
Hydrochloric Acid SCHEMBL27551812 0.98 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4GABRA1
SCHEMBL27557359 0.98 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4GABRA1
Hydrochloric Acid SCHEMBL8615963 0.98 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4GABRA1
Ethylene SCHEMBL8592522 0.96 MEN1 (0.44) MEN1KMT2ACYP1A2CYP3A4GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
EP-2454229-B1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN RISEN (SHANGHAI) PHARMA TECH CO LTD (CN) 2017-09-13 EP disclosed
US-20160220519-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN LU, Jiasheng (CN) 2016-08-04 US disclosed
US-20160220519-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN LU, Jiasheng (CN) 2016-08-04 US disclosed
US-9233913-B2 Amino acid derivatives for the treatment of neuropathic pain Kong, Xianqi (CA) 2016-01-12 US disclosed
US-9233913-B2 Amino acid derivatives for the treatment of neuropathic pain Kong, Xianqi (CA) 2016-01-12 US disclosed
US-20140171507-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2014-06-19 US disclosed
US-20140171507-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2014-06-19 US disclosed
US-20120208876-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2012-08-16 US disclosed
US-20120208876-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2012-08-16 US disclosed
WO-2010127439-A1 AMMO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MEN1 659/4885KMT2A 4839/4885CYP1A2 2104/4885
US-20140171507-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN GAP43, OPRL1, NGF MEN1 4550/4885KMT2A 3055/4885CYP1A2 3871/4885
US-20160220519-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN GAP43, OPRL1, NGF MEN1 4553/4885KMT2A 3047/4885CYP1A2 3783/4885
US-20120208876-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN GAP43, OPRL1, NGF MEN1 4550/4885KMT2A 3055/4885CYP1A2 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.